Resource Filter: 1-5
Discovery of WTX-518, an IL-18 Pro-drug That is Conditionally Activated Within the Tumor Microenvironment and Induces Regressions in Mouse Tumor Models
Date
Comprehensive characterization of IFNγ signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies
Date
Spatial Analysis of Tumor Infiltrating Lymphocyte Populations in Syngeneic Mouse Tumor Models After Treatment with IL-12 (mWTX-330) or IL-2 (WTX-124) INDUKINE™ Molecules
Date
The Combination of ACT and INDUKINE™ Therapy Leads to Improved Antitumor Immunity in Mouse Solid Tumors
Date
Development of WTX-712, a Conditionally Active IL-21 INDUKINETM Molecule for the Treatment of Cancer
Date
Optimal Antitumor Immunity is Triggered by WTX-124, a Clinical Stage Conditionally Activated INDUKINE™ Molecule that Releases Fully Potent IL-2 into the Tumor Microenvironment
Date
Super-enhancer hijacking drives ectopic expression of hedgehog pathway ligands in meningiomas
Date
Targeted removal of macrophage-secreted interleukin-1 receptor antagonist protects against lethal Candida albicans sepsis
Date
Macrophage-endothelial cell crosstalk orchestrates neutrophil recruitment in inflamed mucosa
Date
Automation of Proximity Ligation Immunoassay for interaction between PD-L1 and PD-1 detection in the tumor microenvironment using microfluidic-based systems
Date
